61
Participants
Start Date
September 17, 2020
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2028
ME-401
In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
Anjo Kosei Hospital, Anjo
Aichi Cancer Center Hospital, Nagoya
Japanese Red Cross Nagoya Daini Hospital, Nagoya
National Hospital Organization Nagoya Medical Center, Nagoya
Kameda Medical Center, Kamogawa
National Hospital Organization Shikoku Cancer Center, Matsuyama
Gunma University Hospital, Maebashi
Chugoku Central Hospital, Fukuyama
Hokkaido University Hospital, Sapporo
Ishikawa Prefectural Central Hospital, Kanazawa
Mie University Hospital, Tsu
Tohoku University Hospital, Sendai
Kurashiki Central Hospital, Kurashiki
Kindai University Hospital, Sayama
Osaka University Hospital, Suita
Saitama Medical University International Medical Center, Hidaka
Jichi Medical University Hospital, Shimotsuke
Tokyo Metropolitan Komagome Hospital, Bunkyo-ku
National Cancer Center Hospital, Chuo-ku
The Cancer Institute Hospital Of JFCR, Koto-ku
Tottori University Hospital, Yonago
Akita University Hospital, Akita
Aomori Prefectural Central Hospital, Aomori
Chiba Cancer Center, Chiba
Kyushu University Hospital, Fukuoka
National Hospital Organization Kyushu Medical Center, Fukuoka
Kagoshima University Hospital, Kagoshima
National Hospital Organization Kumamoto Medical Center, Kumamoto
Japanese Red Cross Kyoto Daini Hospital, Kyoto
Okayama University Hospital, Okayama
Kyowa Kirin Co., Ltd.
INDUSTRY